Unum Therapeutics Inc. (UMRX) recently stated financial results and corporate updates for the 3rd quarter ended September 30, 2019, and supplied current activities.
On 21 Jan 2020, Unum Therapeutics Inc. (NASDAQ: UMRX) stock observed trading -78.39% off 52-week high price. On the other end, the stock has been kept in mind 121.15% far from low cost over the last 52-weeks. The stock divulged a relocation of 34.97% away from 50 day moving average and -47.66% far from 200 day moving average. Moving more detailed, we can see that shares have been trading 31.00% off 20-day moving average.
Third Quarter 2019 Financial Results
UMRXs shares are at -29.36% for the quarter and driving a -74.51% return throughout the previous year and is now at 46.15% because this point in 2018. The USA based company Unum Therapeutics Inc. moved with change of 10.88% to $1.05 with the overall traded volume of 443554 shares in current session versus to a typical volume of 327.84 K.
Cash and Cash Equivalents: As of September 30, 2019, Unum had money and cash equivalents of $45.9 M. Unum believes that its existing cash and money equivalents will money operating costs and capital expenditure requirements into early 2021.
G&A Expenses: General and administrative expenditures for the third quarter ended September 30, 2019 were $2.7 M, contrast to $2.4 M for the exact same period of 2018. The increase is mostly associated with increased headcount and personnel-related costs as well as expenses needed to run as a public company.
Bottom line: Net loss attributable to regular stockholders was $12.0 M, or $0.39 per share, for the 3rd quarter ended September 30, 2019 contrast with a net loss attributable to common shareholders of $10.2 M, or $0.34 per share, for the same period of 2018.
R&D Expenses: Research and advancement costs were $10.3 M for the 3rd quarter ended September 30, 2019 contrast to $10.3 M for the exact same duration of 2018. Research and development expenditures relate to expenses for the continuous Phase 1 trials and preclinical programs, as well as personnel-related costs to support these programs.
Alliance Revenue: Alliance profits acknowledged throughout the third quarter ended September 30, 2019 was $1.0 M, contrast to $2.0 M in the same period of 2018. Alliance profits, that includes the recognition of a part of the in advance payment gotten from Seattle Genetics, Inc. in addition to compensations of research and advancement expenses credited to the Seattle Genetics, Inc. alliance contract, lowered as an outcome of fewer activities related to the programs under the alliance agreement.
On the other end, the stock has been kept in mind 121.15% away from low rate over the last 52-weeks. The stock revealed a move of 34.97% away from 50 day moving average and -47.66% away from 200 day moving average. Moving closer, we can see that shares have actually been trading 31.00% off 20-day moving average.